Biotech IPOs

Jeff Meacham is a drug analyst at B of A Securities. He says that the dramatic rise and fall in biotech had a lot to do with a broader shift in investor tastes. Mature companies with dependable cash flows are more popular, including some big drug companies. Jeff says that investors could sell big pharma stocks if the economy improves but he doesn't see that as likely over the next six months.